Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study will evaluate the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
Epistemonikos ID: a3f58983c9515dd26815eca04d2b651beb5884e5
First added on: May 07, 2024